LLY

972.6

-0.58%↓

JNJ

189.2

+1.42%↑

UNH

321.16

-0.66%↓

NVS

128.81

+1.41%↑

ABT

125.86

+0.47%↑

LLY

972.6

-0.58%↓

JNJ

189.2

+1.42%↑

UNH

321.16

-0.66%↓

NVS

128.81

+1.41%↑

ABT

125.86

+0.47%↑

LLY

972.6

-0.58%↓

JNJ

189.2

+1.42%↑

UNH

321.16

-0.66%↓

NVS

128.81

+1.41%↑

ABT

125.86

+0.47%↑

LLY

972.6

-0.58%↓

JNJ

189.2

+1.42%↑

UNH

321.16

-0.66%↓

NVS

128.81

+1.41%↑

ABT

125.86

+0.47%↑

LLY

972.6

-0.58%↓

JNJ

189.2

+1.42%↑

UNH

321.16

-0.66%↓

NVS

128.81

+1.41%↑

ABT

125.86

+0.47%↑

Search

Merck & Co Inc.

Gesloten

SectorGezondheidszorg

88.72 2.54

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

85.77

Max

86.89

Belangrijke statistieken

By Trading Economics

Inkomsten

-656M

4.4B

Verkoop

1.5B

17B

K/W

Sectorgemiddelde

10.911

77.256

EPS

2.58

Dividendrendement

3.72

Winstmarge

28.021

Werknemers

73,000

EBITDA

322M

6.7B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+10.51% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.72%

2.33%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-14B

206B

Vorige openingsprijs

86.18

Vorige sluitingsprijs

88.72

Nieuwssentiment

By Acuity

27%

73%

74 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Merck & Co Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 nov 2025, 13:03 UTC

Acquisities, Fusies, Overnames

Merck Taking Full Control of MK-8690 Development Program

30 okt 2025, 10:45 UTC

Winsten

Merck 3Q Profit Rises on Strong Keytruda Demand

13 okt 2025, 12:19 UTC

Belangrijke Marktbewegers

Bicara Shares Rise Premarket on FDA Breakthrough Designation

11 aug 2025, 12:43 UTC

Belangrijke Marktbewegers

IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data

29 jul 2025, 10:45 UTC

Winsten

Merck & Co. to Lay Off Workers, Reduce Real Estate to Invest in New Products

30 okt 2025, 13:49 UTC

Winsten

Merck Stock Falls. Sales of Key Products Missed Estimates. -- Barrons.com

30 okt 2025, 11:32 UTC

Winsten

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30 okt 2025, 10:51 UTC

Winsten

Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time. -- Barrons.com

30 okt 2025, 10:30 UTC

Winsten

Merck 3Q Keytruda Sales Up 10% >MRK

30 okt 2025, 10:30 UTC

Winsten

Merck 3Q Keytruda Sales $8.14B >MRK

7 okt 2025, 10:45 UTC

Acquisities, Fusies, Overnames

Merck Completes Acquisition Of Verona Pharma >MRK VRNA

29 jul 2025, 11:13 UTC

Winsten

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29 jul 2025, 10:45 UTC

Winsten

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29 jul 2025, 10:30 UTC

Winsten

Merck: Updated FY Adj EPS Outlook Does Not Include Anticipated Impact of Verona Pharma Acquisition >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: $200M of Costs Related to Impact of Tariffs in FY Outlook Unchanged Vs Previous Guidance Pending Outcome of Additional Potential Government Actions >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: As Part of Initiative, Approved New Restructuring Program in Which Co. Expects to Eliminate Certain Administrative, Sales and R&D Positions >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: Updated FY Adj EPS Outlook Includes Revised Negative Impact of Foreign Exchange of About 15c/Shr >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: For Latest 2Q, Recorded Charges of $649M Related to Restructuring Program >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck Narrows FY View To Sales $64.3B-$65.3B Vs Prior View $64.1B-$65.6B >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: Expect Actions Under Restructuring Program to Result in Annual Cost Savings of About $1.7B, Which Will Be Substantially Realized by End of 2027 >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: Will Continue to Hire Employees Into New Roles Across Strategic Growth Areas of the Business >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: Restructuring Program Is Part of the Multiyear Optimization Initiative Expected to Achieve $3B in Annual Cost Savings by End of 2027 >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck Sees Cumulative Pretax Costs Related to Program to Be About $3B >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck Launching New Multiyear Optimization Initiative to Enable Transformation of CO's Portfolio by Generating Expected $3B in Annual Cost Savings From Productivity Actions >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: Savings Will Be Fully Reinvested to Support New Product Launches and Pipeline Across Multiple Therapeutic Areas >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: Will Reduce Global Real-Estate Footprint and Continue to Optimize Manufacturing Network, Aligning Geography of Global Manufacturing to Co's Customers >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck 2Q Winrevair Sales $336M >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck 2Q Keytruda Sales Up 9% >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck: Lower Gardasil/Gardasil 9 and Januvia/Janumet Sales Primarily Due to Lower Demand in China >MRK

29 jul 2025, 10:30 UTC

Winsten

Merck 2Q Gardasil/Gardasil 9 Sales Down 55% >MRK

Peer Vergelijking

Prijswijziging

Merck & Co Inc. Prognose

Koersdoel

By TipRanks

10.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 95.35 USD  10.51%

Hoogste 120 USD

Laagste 82 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck & Co Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

4

Buy

8

Hold

0

Sell

Technische score

By Trading Central

76.03 / 83.28Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

74 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat